Patient characteristics and adiponectin concentrations among subgroups
| Characteristic . | Number . | Value . | HMW adiponectin, μg/mL (mean ± SD) . | Univariate P . | Multivariate β-coefficient (95% CI) . | P . |
|---|---|---|---|---|---|---|
| Sex, n | ||||||
| Male | 18 | 7.9 ± 6.0 | .0008 | — | — | |
| Female | 16 | 18.9 ± 10.8 | 9.1 (3.9-14.3) | .0013 | ||
| Median age, y (range) | 38.5 | (16-65) | 0.0002 ± 0.11* | NS | — | — |
| Median weight loss from SCT, kg (range) | 4.1 | (−16.9-26.5) | 0.14 ± 0.22* | NS | — | — |
| Median body mass index at time of sampling, kg/m2 (range) | 19.1 | (15.3-34.6) | 1.0 ± 0.41* | .016 | NS | — |
| Conditioning regimen | ||||||
| Cy/TBI | 19 | 10.1 ± 8.5 | NS | — | — | |
| Cytarabine/TBI | 1 | 18.6 | ||||
| RIC | 15 | 16.4 ± 11.4 | ||||
| Donor sex | ||||||
| Male | 16 | 10.8 ± 9.7 | NS | — | — | |
| Female | 18 | 15.2 ± 10.3 | ||||
| Donor source | ||||||
| Matched related | 10 | 11.8 ± 12.2 | NS | — | — | |
| Matched unrelated | 13 | 13.5 ± 9.5 | ||||
| Mismatched related | 6 | 12.9 ± 8.3 | ||||
| Mismatched unrelated | 5 | 15.0 ± 11.9 | ||||
| Bone marrow or peripheral blood | ||||||
| Bone marrow | 19 | 14.1 ± 9.7 | NS | — | — | |
| Peripheral blood | 15 | 11.9 ± 10.9 | ||||
| aGVHD | ||||||
| Grade 0 or 1 | 20 | 11.3 ± 9.3 | NS | — | — | |
| Grade 2-4 | 14 | 15.7 ± 11.0 | ||||
| Type of GVHD at sampling | ||||||
| None | 10 | 7.0 ± 5.0 | .031 | NA | — | |
| Late onset aGVHD | 2 | 7.2 ± 3.0 | ||||
| cGVHD (classic/overlapped) | 22 (19/3) | 6.4 ± 10.9 | ||||
| Severity of cGVHD at sampling | ||||||
| None + late aGVHD | 12 | 7.1 ± 4.6 | .031 | — | — | |
| Mild | 11 | 13.6 ± 12.0 | 5.3 (−0.93-11.5) | .09 | ||
| Moderate | 7 | 19.1 ± 8.4 | 9.0 (2.3-15.7) | .011 | ||
| Severe | 4 | 19.4 ± 12.1 | 15.4 (7.2-23.6) | .0006 | ||
| Organ involvements of cGVHD at sampling | ||||||
| Skin | 11 | 14.9 ± 9.7 | NS | — | — | |
| Mouth | 16 | 16.3 ± 9.7 | NS | — | — | |
| Eye | 3 | 17.9 ± 9.0 | NS | — | — | |
| Gut | 3 | 26.0 ± 14.1 | .022 | NS | — | |
| Liver | 10 | 15.3 ± 7.7 | NS | — | — | |
| Other | 4 | 17.6 ± 7.9 | NS | — | — | |
| Lung (BO/BOOP) | 0/1 | — | — | — | — | |
| Muscle/joint | 1 | — | — | — | — | |
| Genital tract | 1 | — | — | — | — | |
| Serositis | 1 | — | — | — | — | |
| Steroid use at sampling day | ||||||
| No administration | 17 | 9.2 ± 6.4 | .021 | — | — | |
| On administration | 17 | 17.0 ± 11.8 | — | 6.9 (1.7-12.1) | .012 |
| Characteristic . | Number . | Value . | HMW adiponectin, μg/mL (mean ± SD) . | Univariate P . | Multivariate β-coefficient (95% CI) . | P . |
|---|---|---|---|---|---|---|
| Sex, n | ||||||
| Male | 18 | 7.9 ± 6.0 | .0008 | — | — | |
| Female | 16 | 18.9 ± 10.8 | 9.1 (3.9-14.3) | .0013 | ||
| Median age, y (range) | 38.5 | (16-65) | 0.0002 ± 0.11* | NS | — | — |
| Median weight loss from SCT, kg (range) | 4.1 | (−16.9-26.5) | 0.14 ± 0.22* | NS | — | — |
| Median body mass index at time of sampling, kg/m2 (range) | 19.1 | (15.3-34.6) | 1.0 ± 0.41* | .016 | NS | — |
| Conditioning regimen | ||||||
| Cy/TBI | 19 | 10.1 ± 8.5 | NS | — | — | |
| Cytarabine/TBI | 1 | 18.6 | ||||
| RIC | 15 | 16.4 ± 11.4 | ||||
| Donor sex | ||||||
| Male | 16 | 10.8 ± 9.7 | NS | — | — | |
| Female | 18 | 15.2 ± 10.3 | ||||
| Donor source | ||||||
| Matched related | 10 | 11.8 ± 12.2 | NS | — | — | |
| Matched unrelated | 13 | 13.5 ± 9.5 | ||||
| Mismatched related | 6 | 12.9 ± 8.3 | ||||
| Mismatched unrelated | 5 | 15.0 ± 11.9 | ||||
| Bone marrow or peripheral blood | ||||||
| Bone marrow | 19 | 14.1 ± 9.7 | NS | — | — | |
| Peripheral blood | 15 | 11.9 ± 10.9 | ||||
| aGVHD | ||||||
| Grade 0 or 1 | 20 | 11.3 ± 9.3 | NS | — | — | |
| Grade 2-4 | 14 | 15.7 ± 11.0 | ||||
| Type of GVHD at sampling | ||||||
| None | 10 | 7.0 ± 5.0 | .031 | NA | — | |
| Late onset aGVHD | 2 | 7.2 ± 3.0 | ||||
| cGVHD (classic/overlapped) | 22 (19/3) | 6.4 ± 10.9 | ||||
| Severity of cGVHD at sampling | ||||||
| None + late aGVHD | 12 | 7.1 ± 4.6 | .031 | — | — | |
| Mild | 11 | 13.6 ± 12.0 | 5.3 (−0.93-11.5) | .09 | ||
| Moderate | 7 | 19.1 ± 8.4 | 9.0 (2.3-15.7) | .011 | ||
| Severe | 4 | 19.4 ± 12.1 | 15.4 (7.2-23.6) | .0006 | ||
| Organ involvements of cGVHD at sampling | ||||||
| Skin | 11 | 14.9 ± 9.7 | NS | — | — | |
| Mouth | 16 | 16.3 ± 9.7 | NS | — | — | |
| Eye | 3 | 17.9 ± 9.0 | NS | — | — | |
| Gut | 3 | 26.0 ± 14.1 | .022 | NS | — | |
| Liver | 10 | 15.3 ± 7.7 | NS | — | — | |
| Other | 4 | 17.6 ± 7.9 | NS | — | — | |
| Lung (BO/BOOP) | 0/1 | — | — | — | — | |
| Muscle/joint | 1 | — | — | — | — | |
| Genital tract | 1 | — | — | — | — | |
| Serositis | 1 | — | — | — | — | |
| Steroid use at sampling day | ||||||
| No administration | 17 | 9.2 ± 6.4 | .021 | — | — | |
| On administration | 17 | 17.0 ± 11.8 | — | 6.9 (1.7-12.1) | .012 |
P < .05 was considered significant.
CI indicates confidence interval; Cy, cyclophosphamide; TBI, total body irradiation; RIC, reduced intensity conditioning; aGVHD, acute GVHD; BO, bronchiolitis obliterans; BOOP, bronchiolitis obliterans organizing pneumonia; NS, not significant; —, not applicable; and NA, not assessed.
Changes in adiponectin are shown with a 1-unit increase in continuous variables.